Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell LymphomaGrade IIIB Follicular Lymphoma
- Registration Number
- NCT01715961
- Lead Sponsor
- Centre Henri Becquerel
- Brief Summary
This clinical trial is a multicentric prospective study to assess the clinical and prognostic value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
- Detailed Description
Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 98
- Patients >= 70 years
- DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade lymphoma
- Whatever the IPI score and the performance status
- Treated by Rituximab-CHOP or Rituximab-mini-CHOP
- CT scan imaging performed one month or less before inclusion
- Signed informed consent
- No initial CT scan imaging performed more than one month before inclusion
- Positivity for HCV, HBV and HIV
- Anthracycline contra-indication
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method progression free survival at 18 months
- Secondary Outcome Measures
Name Time Method progression free survival at 24 months rate of over grade 2 toxicities at the first and second courses of chemotherapy (day 21 and day 42) determination of both molecular subtypes GCB and ABC at 24 months according DASL technology (c-DNA mediated annealing selection extension and ligation)
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
Centre Henri Becquerel
🇫🇷Rouen, France
Centre Henri Becquerel🇫🇷Rouen, France